Galli Mario, Tarantino Fabio, Mameli Stefano, Zerboni Santino, Butti Elena, Sagone Antonio, Passerini Francesco, Cappucci Alessandro, Ferrari Giovanni
Catheterization Laboratory, Cardiology Department, S. Anna Hospital, Como, Italy.
J Invasive Cardiol. 2002 Jul;14(7):386-90.
Stent implantation of renal stenosis (RS) has been reported on extensively; this technique is perceived as superior to balloon angioplasty alone and less invasive than surgical revascularization. With the development of new accessories and stents, we can now improve and optimize procedural and clinical results. In this pilot study, we tested an alternative minimally invasive approach for renal stenting: the transradial artery catheterization (TAC) and a 6 French (Fr) system for stenting.
In this feasibility study, we enrolled patients with RS uncontrolled hypertension and/or chronic renal insufficiency. After assuring good dual blood supply (Allen test), TAC was attempted. The guiding catheters chosen for stenting were 6 Fr (0.70 ) Zuma 2 (Medtronic AVE, Santa Rosa, California). The selection of the guiding catheter was performed with respect to back-up support and coaxial alignment. RS were crossed with a coronary extra support guidewire (0.0.14 mailman, Boston Scientific/Scimed, Maple Grove, Minnesota). A balloon angioplasty before stenting was performed only in presence of subocclusive calcified stenosis, otherwise direct stenting was performed. We used low profile stents (12 16 mm LP Sulzer stent, IntraTherapeutics Inc., Minnesota) manually crimped on monorail balloon (5.0 6.0 mm x 20 mm). Immediately after completion of the procedure, the sheath was removed and a selective radial artery compression device was used for hemostasis. Patients were not restricted to bedrest, but were discharged the following day.
There were 25 patients in the study population. Procedural indications were poorly controlled hypertension in 15/25 patients and/or preservation of renal function in 10/25 patients. Procedural success was obtained in 27/27 lesions (100%). Direct stenting was performed in 24/27 stenosis; predilatation was necessary in 3/27. We used 1 stent per lesion. The mean fluoro time was 7 5 minutes/lesion and mean procedural time was 14 5 minutes/lesion. No procedural and clinical complications occurred during the procedures upon the discharge.
Our results confirmed the safety of this approach in the treatment of RS. The devices used in the study were those traditionally used for coronary procedures. The adoption of these materials and techniques have simplified the procedure and has permitted a reduction of fluoro and procedural time. An additional advantage has been the passive achievement of hemostasis by pressure devices reducing the workload of nursing and medical staff with elimination of bleeding complications that allowed immediate post procedural ambulation.
肾动脉狭窄(RS)的支架植入术已有广泛报道;该技术被认为优于单纯球囊血管成形术,且比外科血管重建术侵入性更小。随着新附件和支架的发展,我们现在可以改善和优化手术及临床结果。在这项初步研究中,我们测试了一种用于肾动脉支架植入的替代微创方法:经桡动脉插管(TAC)和用于支架植入的6法国(Fr)系统。
在这项可行性研究中,我们纳入了患有RS且高血压控制不佳和/或慢性肾功能不全的患者。在确保良好的双重血供(艾伦试验)后,尝试进行TAC。选择用于支架植入的心导管为6 Fr(0.70)Zuma 2(美敦力AVE,加利福尼亚州圣罗莎)。根据支撑力和同轴对齐情况选择心导管。使用冠状动脉额外支撑导丝(0.014 mailman,波士顿科学/Scimed,明尼苏达州枫叶谷)穿过RS。仅在存在亚闭塞性钙化狭窄时才在支架植入前进行球囊血管成形术,否则进行直接支架植入。我们使用在单轨球囊(5.0 6.0 mm×20 mm)上手动压接的低轮廓支架(12 16 mm LP Sulzer支架,IntraTherapeutics公司,明尼苏达州)。手术完成后立即移除鞘管,并使用选择性桡动脉压迫装置进行止血。患者不限卧床休息,但次日出院。
研究人群中有25例患者。手术指征为15/25例患者高血压控制不佳和/或10/25例患者肾功能保留。27/27个病变(100%)手术成功。24/27例狭窄进行了直接支架植入;3/27例需要预扩张。每个病变使用1个支架。平均透视时间为7±5分钟/病变,平均手术时间为14±5分钟/病变。出院时手术过程中未发生手术和临床并发症。
我们的结果证实了这种方法治疗RS的安全性。研究中使用的设备是传统用于冠状动脉手术的设备。采用这些材料和技术简化了手术过程,并减少了透视和手术时间。另一个优点是通过压迫装置被动实现止血,减少了护理和医务人员的工作量,消除了出血并发症,使患者术后能够立即活动。